Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Authors:
- Björn HackansonBHBjörn Hackanson
- Manfred JungMJManfred Jung
Open Access
- 9 November 2010
- journal article
- website
- Published by Springer Nature in Clinical Epigenetics
- Vol. 1 (3-4) , 117-136
Abstract
Encompassing the broad spectrum of epigenetics research from basic research to innovations in therapeutic treatments, Clinical Epigenetics is a top tier, open ...Keywords
This publication has 133 references indexed in Scilit:
- Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumoursEuropean Journal of Cancer, 2010
- Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib MesylateCancer Cell, 2010
- Chemical phylogenetics of histone deacetylasesNature Chemical Biology, 2010
- Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)Cancer, 2009
- Genome-wide Mapping of HATs and HDACs Reveals Distinct Functions in Active and Inactive GenesCell, 2009
- HDAC expression and clinical prognosis in human malignanciesCancer Letters, 2009
- Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)Investigational New Drugs, 2008
- The Epigenomics of CancerCell, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Epigenetic therapy of cancer: past, present and futureNature Reviews Drug Discovery, 2006